Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 4/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776075 | 0.98 | CHRM5 (0.41) | CHRM5ADRA2CDDB1CRBNOPRM1 | |
| SCHEMBL1778000 | 0.98 | CHRM5 (0.41) | CHRM5ADRA2CDDB1CRBNOPRM1 | |
| SCHEMBL1776362 | 0.98 | CHRM5 (0.41) | CHRM5ADRA2CDDB1CRBNOPRM1 | |
| SCHEMBL19044546 | 0.85 | DDB1 (0.38) | CHRM5DDB1CRBNALKCHRM3 | |
| SCHEMBL1777567 | 0.84 | CHRM5 (0.48) | CHRM5ADRA2COPRM1OPRD1OPRK1 | |
| SCHEMBL9865955 | 0.84 | ACHE (0.38) | DDB1CRBNALK | |
| SCHEMBL1777503 | 0.84 | ALK (0.32) | ALK | |
| SCHEMBL9865525 | 0.84 | GAA (0.42) | ADRA2CDDB1CRBNOPRD1 | |
| SCHEMBL1775870 | 0.84 | GAA (0.42) | ADRA2CDDB1CRBNOPRD1 | |
| SCHEMBL9865948 | 0.84 | ACHE (0.38) | DDB1CRBNALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | claimed |
| EP-1943217-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | claimed |
| US-7943605-B2 | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses | UCB PHARMA S.A. (BE) | 2011-05-17 | — | — | US | disclosed |
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
| EP-1943217-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1866293-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | COASY, FURIN, PEPD | CHRM5 4048/4885ADRA2C 3275/4885DDB1 3906/4885 |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | CHRM5 78/4885ADRA2C 92/4885DDB1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.